LeMaitre Vascular, Inc. - Common Stock (LMAT)

Management details the B. Braun integration timeline and possible supply gaps.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 11.3% year on year to $67.97 million...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

LeMaitre Vascular (NASDAQ:LMAT) reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast. CEO George LeMaitre said on the Nov. 4 earnings call that organic

Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 11.3% year on year to...

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting earnings this Wednesday after the bell. Here’s what you need to know. LeMaitre misse...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...

Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - special...

Artegraft sales surged 34% as gross margins expanded to 72.1%.

LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and As...

Check out the companies making headlines yesterday: LeMaitre (NASDAQ:LMAT): Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell by 18.6% on Wednesday...

What Happened? Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 18.6% in the morning session after the company reported second-quarter r...

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil...

LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relati

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil...

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know. LeM...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...